CORPORATE DETAILS GICS Sector 35: Health Care GICS Industry Group 3510: Health Care Equipment & Services Head Office 51 Leicester Street, Carlton, VIC, 3053 Telephone +61 3 9349 1300 Facsimile +61 3 9348 2689 Website www.cogstate.com
First Listed 28/01/2004 Balance Date 30 June AGM n/a
Dividend Reinvestment? None
PRINCIPAL ACTIVITY Cogstate (CGS) is a biotechnology company focused on diagnostic and therapeutic products for neurodegenerative diseases. Cogstate is also undertaking projects for Alzheimer's disease and Parkinson's disease.
DIAGNOSTICS: Cogstate has designed diagnostics to measure changes in an individual's cognitive performance that can be used in the areas of disease, drugs, trauma, environmental factors stress and depression on brain function. Cogstate has developed CogState, CogSport, CogHealth and CogSafe. The diagnostic products are delivered via the Internet and are designed to assess changes in attention, executive function and memory. Cogstate is designed for pharmaceutical and medical device companies, private and government research and academic institutions and used to measure cognition in the study of drugs affecting the nervous system. CogSport allows sports physicians to make decisions about the recovery of brain function after sports-related concussions. CogHealth is designed as part of an annual physical examination in patients over the age of 50 for detection of early Alzheimer's disease. Cogsafe has been developed for use in occupational health and safety environments.
THERAPEUTICS: Cogstate is developing therapeutic projects for Alzheimer's disease and Parkinson's disease. The Alzheimer's disease project is focused on compounds licensed from Japanese based Taisho Pharmaceutical Co Limited. The compounds are in the preclinical stage of development and no human data has been obtained. The Parkinson's disease project was licensed from Brain Research Limited, associated with Professor Shlomo Yehuda from Bar Ilan University in Israel. The project is set to increase dopamine available to brain cell levels through increasing levels of the metabolic precursor to dopamine, tyrosine.
DIRECTORS Dr Peter Bick Miss Geoff Brooke Mr David Darby Mr Richard Morgan Mr Martyn K Myer Dr Michael Wooldridge
PRINCIPALS Chairman Mr Martyn K Myer MD/CEO Dr Peter Bick Company Secretary Mr Andrew Lord Mr Bradley O'Connor
ADVISERS Auditors Ernst & Young
Solicitors Watermark
Bankers n/a
REGISTRY Name ASX Perpetual Registrars Limited Registry Address Level 4, 333 Collins St, Melbourne, VIC, 3000 Registry Postal Address GPO Box 1736P, Melbourne, VIC, 3001 Registry Telephone (03) 9205 4999 Registry Facsimile (03) 9615 9900 Registry TollFree 1300 554 474 Investor Enquiries n/a Broker Number n/a Web Site www.asxperpetual.com.au/index.asp
SUBSTANTIAL SHAREHOLDERS -
LATEST BALANCE Report Effect. Substantial Shareholding % Held at % Held Date Date Shareholder Eff. Date Current ------------------------------------------------------------------------------ N/A 11/02/04 Perpetual Trustees Nominees 8,306,850 23.08 22.15 Ltd N/A 13/02/04 Myer, Martyn Kenneth 2,954,804 8.29 7.88 N/A 13/02/04 Queensland Investment 2,000,000 5.81 5.33 Corporation
Note: % Held Currently refers to the percentage held calculated based on latest total number of shares outstanding.
BALANCES AS AT 2003 ANNUAL REPORT Report Effect. Substantial Shareholding % Held Date Date Shareholder Eff.Date ------------------------------------------------------------------------------ 30/06/03 30/06/03 No substantial shareholders 0N/A Disclosed
SELLS OVER LAST 12 MONTHS Effect. Substantial Prev.% New% ShrsTraded Date Shareholder ------------------------------------------------------------------------------ There were no sells over the last 12 months.
CGS Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
(20min delay)